<DOC>
	<DOCNO>NCT00309491</DOCNO>
	<brief_summary>Primarily , clinical investigation compare efficacy tamoxifen + aminoglutethimide vs. tamoxifen alone term prognosis ( overall survival ) postmenopausal patient potentially curative , operate hormone receptor-positive breast cancer .</brief_summary>
	<brief_title>Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide Postmenopausal Receptor-positive Patients</brief_title>
	<detailed_description />
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Aminoglutethimide</mesh_term>
	<criteria>Postmenopausal patient histologically verify , locoradically treat , invasive minimally invasive breast cancer Hormone receptorpositive status More 6 histologically examine lymph node Laboratory parameter 1. hematopoiesis : &gt; 3500/µl leucocyte , &gt; 100,000/µl thrombocyte 2. renal function : creatinin &lt; 1.5mg % 3. hepatic function : GOT &lt; 2.5 x UNL 4. bilirubin : &lt; 1.5mg % 5. metabolic parameter : Na , Ca , K normal range , normal level blood sugar Concluded heal process follow surgery Less 4 week interval since surgery Informed consent Premenopausal patient , nondeterminable menopausal status Previous radiotherapy , chemotherapy endocrine treatment Generalized disease ( verified lung Xray , skeletal Xray , liver ultrasound ) Contraindications tamoxifen anastrozole T4 tumor ; carcinoma situ Lacking compliance understanding disease Karnofsky Index &lt; 3 Serious concomitant disease Septic complication , systemic infection infectious local process Bilateral ovariectomy ovarian irradiation Second carcinoma status post second carcinoma ( except treat squamous cell carcinoma skin cervical carcinoma situ )</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Tamoxifen</keyword>
	<keyword>Aminoglutethimide</keyword>
	<keyword>Breast cancer</keyword>
</DOC>